225 related articles for article (PubMed ID: 33314800)
1. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.
Artacho A; Isaac S; Nayak R; Flor-Duro A; Alexander M; Koo I; Manasson J; Smith PB; Rosenthal P; Homsi Y; Gulko P; Pons J; Puchades-Carrasco L; Izmirly P; Patterson A; Abramson SB; Pineda-Lucena A; Turnbaugh PJ; Ubeda C; Scher JU
Arthritis Rheumatol; 2021 Jun; 73(6):931-942. PubMed ID: 33314800
[TBL] [Abstract][Full Text] [Related]
2. Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.
Yan H; Su R; Xue H; Gao C; Li X; Wang C
Front Immunol; 2021; 12():789334. PubMed ID: 34975886
[TBL] [Abstract][Full Text] [Related]
3. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis.
Gupta VK; Cunningham KY; Hur B; Bakshi U; Huang H; Warrington KJ; Taneja V; Myasoedova E; Davis JM; Sung J
Genome Med; 2021 Sep; 13(1):149. PubMed ID: 34517888
[TBL] [Abstract][Full Text] [Related]
4. Specific enterotype of gut microbiota predicted clinical effect of methotrexate in patients with rheumatoid arthritis.
Qiao J; Zhang SX; Chang MJ; Cheng T; Zhang JQ; Zhao R; Song S; Liu GY; Chang JS; Li XF
Rheumatology (Oxford); 2023 Mar; 62(3):1087-1096. PubMed ID: 35946529
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate promotes recovery of arthritis-induced alveolar bone loss and modifies the composition of the oral-gut microbiota.
de Arruda JAA; Corrêa JD; Singh Y; Oliveira SR; Machado CC; Schneider AH; Medeiros JD; Fernandes GR; Macari S; Barrioni BR; Santos MS; Duffles LF; Nakaya HTI; Fukada SY; Graves DT; Cunha FQ; Silva TA
Anaerobe; 2022 Jun; 75():102577. PubMed ID: 35490916
[TBL] [Abstract][Full Text] [Related]
6. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
[TBL] [Abstract][Full Text] [Related]
7. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis.
Lundström SL; Hensvold AH; Rutishauser D; Klareskog L; Ytterberg AJ; Zubarev RA; Catrina AI
Arthritis Res Ther; 2017 Aug; 19(1):182. PubMed ID: 28793911
[TBL] [Abstract][Full Text] [Related]
8. Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis.
Plant D; Maciejewski M; Smith S; Nair N; ; Hyrich K; Ziemek D; Barton A; Verstappen S
Arthritis Rheumatol; 2019 May; 71(5):678-684. PubMed ID: 30615300
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
[TBL] [Abstract][Full Text] [Related]
10. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.
Teitsma XM; Jacobs JWG; Welsing PMJ; de Jong PHP; Hazes JMW; Weel AEAM; Pethö-Schramm A; Borm MEA; van Laar JM; Lafeber FPJG; Bijlsma JWJ
Ann Rheum Dis; 2018 Sep; 77(9):1261-1267. PubMed ID: 29760159
[TBL] [Abstract][Full Text] [Related]
11. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
[TBL] [Abstract][Full Text] [Related]
12. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
Wessels JA; van der Kooij SM; le Cessie S; Kievit W; Barerra P; Allaart CF; Huizinga TW; Guchelaar HJ;
Arthritis Rheum; 2007 Jun; 56(6):1765-75. PubMed ID: 17530705
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
Kotrych D; Dziedziejko V; Safranow K; Pawlik A
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
[TBL] [Abstract][Full Text] [Related]
15. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
16. Plasma metabolomic profiling as a tool to identify predictive biomarkers of methotrexate efficacy in rheumatoid arthritis.
Medcalf MR; Bantis LE; Shi P; Bhadbhade P; Gundry RL; Mikuls TR; England BR; O'Dell JR; Funk RS
Semin Arthritis Rheum; 2022 Oct; 56():152056. PubMed ID: 35785666
[TBL] [Abstract][Full Text] [Related]
17. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
18. The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients.
Soukup T; Dosedel M; Pavek P; Nekvindova J; Barvik I; Bubancova I; Bradna P; Kubena AA; Carazo AF; Veleta T; Vlcek J
Rheumatol Int; 2015 Jul; 35(7):1149-61. PubMed ID: 25618758
[TBL] [Abstract][Full Text] [Related]
19. Association of dihydrofolate reductase (DHFR) -317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis.
Milic V; Jekic B; Lukovic L; Bunjevacki V; Milasin J; Novakovic I; Damnjanovic T; Popovic B; Maksimovic N; Damjanov N; Radunovic G; Pejnovic N; Krajinovic M
Clin Exp Rheumatol; 2012; 30(2):178-83. PubMed ID: 22324981
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.
Branco JC; Barcelos A; de Araújo FP; Sequeira G; Cunha I; Patto JV; Oliveira M; Mateus MP; Couto M; Nero P; Pinto P; Monteiro P; Castelão W; Félix J; Ferreira D; Almeida J; Silva MJ
Adv Ther; 2016 Jan; 33(1):46-57. PubMed ID: 26724937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
